These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 36733936)

  • 1. Dual targeting with
    Juzeniene A; Stenberg VY; Bruland ØS; Revheim ME; Larsen RH
    Front Med (Lausanne); 2022; 9():1051825. PubMed ID: 36733936
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In situ Generated
    Stenberg VY; Juzeniene A; Bruland ØS; Larsen RH
    Curr Radiopharm; 2020; 13(2):130-141. PubMed ID: 32389119
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted alpha therapy with the
    Tornes AJK; Stenberg VY; Larsen RH; Bruland ØS; Revheim ME; Juzeniene A
    Front Med (Lausanne); 2022; 9():1058863. PubMed ID: 36507500
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antitumor Activity of Novel Bone-seeking, α-emitting
    Juzeniene A; Bernoulli J; Suominen M; Halleen J; Larsen RH
    Anticancer Res; 2018 Apr; 38(4):1947-1955. PubMed ID: 29599310
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preparation of
    Westrøm S; Generalov R; Bønsdorff TB; Larsen RH
    Nucl Med Biol; 2017 Aug; 51():1-9. PubMed ID: 28486098
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preclinical Development in Radiopharmaceutical Therapy for Prostate Cancer.
    Alati S; Singh R; Pomper MG; Rowe SP; Banerjee SR
    Semin Nucl Med; 2023 Sep; 53(5):663-686. PubMed ID: 37468417
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biodistribution study of
    Sakmár M; Kozempel J; Kučka J; Janská T; Štíbr M; Vlk M; Šefc L
    Nucl Med Biol; 2024; 130-131():108890. PubMed ID: 38402673
    [TBL] [Abstract][Full Text] [Related]  

  • 8. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Radium-223 dichloride bone-targeted alpha particle therapy for hormone-refractory breast cancer metastatic to bone.
    Takalkar A; Adams S; Subbiah V
    Exp Hematol Oncol; 2014; 3():23. PubMed ID: 25243101
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New radiopharmaceutical agents for the treatment of castration-resistant prostate cancer.
    Maffioli L; Florimonte L; Costa DC; Correia Castanheira J; Grana C; Luster M; Bodei L; Chinol M
    Q J Nucl Med Mol Imaging; 2015 Dec; 59(4):420-38. PubMed ID: 26222274
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of separation technology for the removal of radium-223 from targeted thorium conjugate formulations. Part I: purification of decayed thorium-227 on cation exchange columns.
    Frenvik JO; Dyrstad K; Kristensen S; Ryan OB
    Drug Dev Ind Pharm; 2017 Feb; 43(2):225-233. PubMed ID: 27628177
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and characterization of lanthanum phosphate nanoparticles as carriers for (223)Ra and (225)Ra for targeted alpha therapy.
    Rojas JV; Woodward JD; Chen N; Rondinone AJ; Castano CH; Mirzadeh S
    Nucl Med Biol; 2015 Jul; 42(7):614-20. PubMed ID: 25900730
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted Radium Alpha Therapy in the Era of Nanomedicine: In Vivo Results.
    Trencsényi G; Csikos C; Képes Z
    Int J Mol Sci; 2024 Jan; 25(1):. PubMed ID: 38203834
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nano-hydroxyapatite radiolabeled with radium dichloride [
    Gemini-Piperni S; Ricci-Junior E; İlem-Özdemir D; da Silva Batista B; Alencar LMR; Rossi AM; Santos-Oliveira R
    Colloids Surf B Biointerfaces; 2023 Mar; 223():113174. PubMed ID: 36746067
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bone-targeted therapies to reduce skeletal morbidity in prostate cancer.
    Dorff TB; Agarwal N
    Asian J Androl; 2018; 20(3):215-220. PubMed ID: 29553053
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Progress in Targeted Alpha-Particle-Emitting Radiopharmaceuticals as Treatments for Prostate Cancer Patients with Bone Metastases.
    Patel CM; Wadas TJ; Shiozawa Y
    Molecules; 2021 Apr; 26(8):. PubMed ID: 33918705
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bone-targeting radiopharmaceuticals including radium-223.
    Brady D; Parker CC; O'Sullivan JM
    Cancer J; 2013; 19(1):71-8. PubMed ID: 23337760
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dosimetry of bone metastases in targeted radionuclide therapy with alpha-emitting (223)Ra-dichloride.
    Pacilio M; Ventroni G; De Vincentis G; Cassano B; Pellegrini R; Di Castro E; Frantellizzi V; Follacchio GA; Garkavaya T; Lorenzon L; Ialongo P; Pani R; Mango L
    Eur J Nucl Med Mol Imaging; 2016 Jan; 43(1):21-33. PubMed ID: 26266887
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Integrating bone targeting radiopharmaceuticals into the management of patients with castrate-resistant prostate cancer with symptomatic bone metastases.
    Blacksburg SR; Witten MR; Haas JA
    Curr Treat Options Oncol; 2015 Mar; 16(3):325. PubMed ID: 25777571
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase II randomized trial of metastasis-directed therapy with alpha emitter radium-223 in men with oligometastatic castration-resistant prostate cancer (MEDAL).
    Yoshida S; Takahara T; Arita Y; Ito M; Hayakawa S; Oguchi T; Komai Y; Numao N; Yuasa T; Inoue M; Ushijima H; Kudo S; Shimano Y; Nakamura Y; Uchida Y; Uehara S; Tanaka H; Yaegashi H; Izumi K; Yokoyama M; Matsuoka Y; Yoshioka Y; Konishi K; Nakanishi K; Nagahara A; Hirakawa A; Koike R; Koga F; Nishimura K; Mizokami A; Yonese J; Kageyama Y; Yoshimura R; Fujii Y
    BMC Urol; 2023 Mar; 23(1):33. PubMed ID: 36879257
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.